|
 |
| home > ebr > Winter 2002 |
|
|
 PUBLICATIONS |
European BioPharmaceutical Review |
|
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR. |
 |
| |
|
|
| In her Editor's Letter, Dr Helen Abbott gives us a brief synopsis of the range and content of this issue |
|
|
| Opinion - As 2002 closes and a new year begins, Dr Helen Abbott introduces our brand new readers' forum page |
|
|
|
| Despite significant revaluation and restructuring, the biotech sector has reversed its downward trend. In a review of the industry's performance in 2002, G Steven Burrill, CEO of Burrill & Company, reassures us that Biotech Endures |
|
|
| The FT Global Biotech Conference in London recently brought together strategic thinkers from each side of the pond. Dr Helen Abbott, Senior Consultant at Technomark Consulting Services and Editor of EBR, was there |
|
|
| Dr Helen Abbott, EBR's Editor, reports on the 10th Annual BioPartnering Europe (BPE) conference, which covered many diverse aspects of partnering |
|
|
|
|
| Dr Will West, Product Development Director at CellFactors, explains how cell implants and engineered tissues will be able to cure a broad range of health conditions, in Realising the Potential of Human Cells for Therapy |
|
|
In Stem Cells Find a UK Niche - The UK National Stem Cell Initiative, Dr John Sinden, Chief Scientific Officer of ReNeuron Holdings plc, introduces an important new resource for UK researchers
|
|
|
| Traditional validation of potential drug targets can be extremely time-consuming. In Target Validation in the Nervous System using Herpes Simplex Viral Vectors, Dr James Palmer, Senior Scientist, and Dr Robert Coffin, Chief Scientific Officer at BioVex Ltd, propose an alternative method |
|
|
| Bacterial resistance to antibiotics has become a serious threat to public health. Anne Gill, Head of Microbiology at PanTherix Ltd, reminds us of the need for Novel Antibiotics to Counteract the Global Threat of Superbugs |
|
|
| Before attempting drug design we must understand the mechanisms that cause disease at a genetic level. Dr Bob Jackson, Executive Director of R&D at Cyclacel, takes us From Genes to Drugs |
|
|
| Understanding the biological mechanisms that regulate brain function is a daunting task. In Investigating Biomolecular Interactions in Neuropathology: The Role of SPR, Stefan Löfås, Vice President and Chief Scientific Officer of Biacore AB, reviews a powerful new tool |
|
|
| Dr Günter Kraus, Vice President of Research and Development at amaxa GmbH, explores recent progress in the development of Non-Viral Gene Delivery Methods |
|
|
| The large volume of data generated by high-throughput systems means that the selection of relevant information is crucial. Dr Nora Benhabilès, Director of Bioinformatics, and Professor Gérard Marguerie, Chief Scientific Officer at CliniGenetics, discuss New Challenges in Physiogenomics |
|
|
|
| Nick McCooke, Chief Executive Officer of Solexa, considers the potential of genome sequencing services for individuals, in Personal Genomes |
|
|
| In Principled Pragmatism: The UK Perspective on Embryonic Stem Cell Research, Claire Foster of The Church of England's Public Affairs Unit, unravels a complex ethical debate |
|
|
|
| In the post-genomic world, the milestones as well as the endpoints of drug discovery must be protected. Arie M Michelsohn, PhD, JD, Member of the Bio/Pharmaceutical Practice Group at Finnegan, Henderson, Farabow, Garrett & Dunner LLP, goes Beyond the Patented Genome: Protecting Discovery in the New Biology Estate Space |
|
|
| Professor Matthias Herdegen, Director of the Institute of International Law and the Institute for Public Law, University of Bonn, explains Patent Protection for Genes and Other Parts of the Human Body under EC Law |
|
|
| Thierry Calame, Attorney at Law with Lenz & Staehelin, proposes methods of Dealing with the Pitfalls of Intellectual Property Co-Ownership in International Biopharmaceutical R&D Joint Ventures |
|
|
| In Part One of a two-part series, Dr Uta Kцster, Associate with Bardehle Pagenberg, considers Absolute or Limited Product Protection for Biotech Inventions under the relevant EC Directive |
|
|
|
| Sirkka Aura, CEO of Invest in Finland, explains why the country provides a favourable social and economic climate for biotech to prosper, in Overview of the Biotechnology Industry in Finland |
|
|
| In Crossbreeding and Commercial Consolidation in the Uppsala Biotech Cluster, Per Odebrant, Freelance Science and Business Journalist, introduces us to the 'Uppsala Phenomenon' |
|
|
| Dr Helen Abbott, Senior Consultant at Technomark Consulting Services and EBR's Editor, reports on the first Scandinavian BiotechArena Event, held in Malmц, Sweden |
|
|
|
| A taste of what to expect at Cordia EuropaBio Convention 2003 |
|
|
|
| Dr Alcide Barberis, Chief Scientific Officer of ESBATech AG, describes the applicability of cell-based assays to the early phase of drug discovery, in Cell-Based High-Throughput Screens for Drug Discovery |
|
|
| In The Splice of Life, Fabien Schweighoffer PhD, Executive Vice-President of Therapeutic Programs at ExonHit Therapeutics, investigates the advantages of examining cellular events at the mRNA level |
|
|
| How to Truncate RNA Preparation in cRNA Labelling Reactions Without Sacrificing Microarray Performance? Dr Jenny Xiao, Application Scientist at Agilent Technologies, explains |
|
|
| John C Anders, K Chad Bastian and Glenn E Petrie, Research Associates at AAI International, explore the Determination of Absorptivity Constants for Biopharmaceutical Protein Products by Amino Acid Analysis |
|
|
|
|
|
 |
|
|
 |
Industry Events |
 |
EuroBiopartnering 2008
7-9 October 2008, Paris, France
EuroBiOpartnering
2008 gives you the unique opportunity to meet the relevant decision makers and
opinion leaders from the international biotech community and offers you 3 days
of partnering opportunities including one-to-one meetings, company presentations
and further networking activities… Learn
more
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >> |
|
__________________________
__________________________
__________________________
__________________________
|
